drugset / Trial / NCT05902533
REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation
NaSingle-groupOpen-labelTreatment
Summary
To determine the efficacy of reduced elective nodal radiation in anal cancer patients undergoing chemoradiation in reducing toxicity compared to standard nodal irradiation.
Timeline
- Start
- 2023-08-14
- Primary completion
- 2026-08-14
- Completion
- 2029-08-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 825 mg/m2 | Oral |
| Subject | Mitomycin C | Other / unclassified | 10 mg/m2 | Intravenous |